- Home
- FSHP vs EDIT Comparison
FSHP vs EDIT Comparison
Compare FSHP & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- EDIT
- Stock Information
- Founded
- FSHP 2018
- EDIT 2013
- Country
- FSHP United States
- EDIT United States
- Employees
- FSHP N/A
- EDIT N/A
- Industry
- FSHP
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSHP
- EDIT Health Care
- Exchange
- FSHP NYSE
- EDIT Nasdaq
- Market Cap
- FSHP 90.7M
- EDIT 108.1M
- IPO Year
- FSHP 2024
- EDIT 2016
- Fundamental
- Price
- FSHP $10.33
- EDIT $1.13
- Analyst Decision
- FSHP
- EDIT Buy
- Analyst Count
- FSHP 0
- EDIT 14
- Target Price
- FSHP N/A
- EDIT $8.08
- AVG Volume (30 Days)
- FSHP 21.2K
- EDIT 2.4M
- Earning Date
- FSHP 01-01-0001
- EDIT 03-05-2025
- Dividend Yield
- FSHP N/A
- EDIT N/A
- EPS Growth
- FSHP N/A
- EDIT N/A
- EPS
- FSHP 0.17
- EDIT N/A
- Revenue
- FSHP N/A
- EDIT $32,314,000.00
- Revenue This Year
- FSHP N/A
- EDIT N/A
- Revenue Next Year
- FSHP N/A
- EDIT N/A
- P/E Ratio
- FSHP $62.54
- EDIT N/A
- Revenue Growth
- FSHP N/A
- EDIT N/A
- 52 Week Low
- FSHP $9.99
- EDIT $1.12
- 52 Week High
- FSHP $10.35
- EDIT $7.13
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- EDIT 38.21
- Support Level
- FSHP N/A
- EDIT $1.24
- Resistance Level
- FSHP N/A
- EDIT $1.32
- Average True Range (ATR)
- FSHP 0.00
- EDIT 0.10
- MACD
- FSHP 0.00
- EDIT -0.03
- Stochastic Oscillator
- FSHP 0.00
- EDIT 2.27
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.